UC HEALTH LINE: For Parkinson's Prevention, Is Espresso Worth a Shot?
And now, says UC neurologist Alberto Espay, MD, coffeeparticularly its natural stimulant known as caffeineis turning heads as a possible prevention for Parkinsons disease.
Recent studies have shown that coffee drinkers are less likely to develop Parkinsons. And new laboratory studies have looked at how caffeine works in the brain and determined that it can enhance the effects of the most common drug given to Parkinsons patients, levodopa.
In fact, scientists are currently working on drugs for Parkinsons that act on the brain in the same way caffeine does, says Espay.
With all we know about coffee, Espay says, if you drink it, keep drinking. And if you dont, it wouldnt hurt to start.
Its unclear what amount of coffee must be consumed to have the most benefit, he adds. But because coffee has no clear health risks, go for it. Just be sure to talk with your doctor first if you have high blood pressure or other health concerns.
Parkinsons is a disease that results from the loss of a group of brain cells that produce the natural neurotransmitter dopamine. Without dopamine, brain nerve cells dont fire properly, causing an inability to control movement.
The most visible signs of the diseasetremors, difficulty with gait and balance, rigidity and stiffness or general slowness when movingare blamed on this lack of dopamine production in the brain.
But, Espay says, there are other signs and symptoms of Parkinsons disease that usually appear much earlier and are not directly related to insufficient dopamine. They include sleep difficulties, loss of sense of smell, constipation and depression.
The Parkinsons Disease Foundation estimates as many as 1 million Americans have Parkinsons disease and many go undiagnosed.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.